Clinical Trial Update: Surufatinib Combined With KN046 and AG Regimen Chemotherapy as First-Line Treatment for Unresectable Advanced Pancreatic Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is investigating surufatinib combined with KN046 and AG regimen chemotherapy as first-line treatment for unresectable locally advance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Gemcitabine (Gemcitabine)
• KN046
• Nab-paclitaxel (paclitaxel protein-bound)
• Surufatinib (Surufatinib)

Snippet

Sponsor: Shanghai Zhongshan Hospital | Conditions: Unresectable Locally Advanced or Metastatic Pancreatic Cancer | Phase 1, Phase 2 | Status: UNKNOWN